Sinphar PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 4/6
Sinphar PharmaceuticalLtd has a total shareholder equity of NT$3.4B and total debt of NT$1.9B, which brings its debt-to-equity ratio to 57.2%. Its total assets and total liabilities are NT$6.3B and NT$2.9B respectively. Sinphar PharmaceuticalLtd's EBIT is NT$288.7M making its interest coverage ratio 13.5. It has cash and short-term investments of NT$1.1B.
Key information
57.2%
Debt to equity ratio
NT$1.94b
Debt
| Interest coverage ratio | 13.5x |
| Cash | NT$1.08b |
| Equity | NT$3.40b |
| Total liabilities | NT$2.85b |
| Total assets | NT$6.25b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1734's short term assets (NT$2.6B) exceed its short term liabilities (NT$1.2B).
Long Term Liabilities: 1734's short term assets (NT$2.6B) exceed its long term liabilities (NT$1.6B).
Debt to Equity History and Analysis
Debt Level: 1734's net debt to equity ratio (25.4%) is considered satisfactory.
Reducing Debt: 1734's debt to equity ratio has increased from 51.5% to 57.2% over the past 5 years.
Debt Coverage: 1734's debt is not well covered by operating cash flow (15.2%).
Interest Coverage: 1734's interest payments on its debt are well covered by EBIT (13.5x coverage).